The activist investor claims Pfizer failed to capitalize on the windfall earned from its COVID-19 vaccine and, in the process, destroyed tens of billions of dollars in market value.
Global Klinefelter Syndrome Therapeutics MarketThe global Klinefelter Syndrome Therapeutics Market is projected to surpass ...
Valuation metrics show AbbVie to be only slightly undervalued based on FY 2025 projections. Read why I'm neutral on ABBV ...
Monday announced that nine provinces have approved accelerated public coverage of Epkinly, a treatment for adult ...
The global kinase inhibitor in autoimmune diseases market is projected to grow steadily over the next decade, according to a ...
Narus Financial Partners LLC boosted its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 8.4% in the 3rd quarter, ...
From Fortune 500 firms to startups, Crain's exclusive list reveals the Chicago-area companies inventing new ways of doing ...
On October 18, 2024, Abbott Laboratories Employees Credit Union (“ALEC”) filed a notice of data breach with the Attorney ...
AbbVie (NYSE:ABBV – Free Report) had its target price upped by BMO Capital Markets from $214.00 to $220.00 in a research note ...
WisdomTree US Quality Dividend Growth (DGRW), and the iShares Core Dividend Growth (DGRO) are some of the most popular dividend-focused ETFs in Wall Street, with $102 billion, $15 billion, and $30.7 ...
The US Food and Drug Administration has approved VYALEV, a groundbreaking therapy developed by AbbVie to treat adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback